Literature DB >> 2394002

Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group.

E M Ohman1, R M Califf, E J Topol, R Candela, C Abbottsmith, S Ellis, K N Sigmon, D Kereiakes, B George, R Stack.   

Abstract

To determine the clinical consequences of reocclusion of an infarct-related artery after reperfusion therapy, we evaluated 810 patients with acute myocardial infarction. Patients were admitted into four sequential studies with similar entry criteria in which patency of the infarct-related artery was assessed by coronary arteriography 90 minutes after onset of thrombolytic therapy. Successful reperfusion was established acutely in 733 patients. Thrombolytic therapy included tissue-type plasminogen activator (t-PA) in 517, urokinase in 87, and a combination of t-PA and urokinase in 129 patients. All patients received aspirin, intravenous heparin and nitroglycerin, and diltiazem during the recovery phase. A repeat coronary arteriogram was performed in 88% of patients at a median of 7 days after the onset of symptoms. Reocclusion of the infarct-related artery occurred in 91 patients (12.4%), and 58% of these were symptomatic. Angiographic characteristics at 90 minutes after thrombolytic therapy that were associated with reocclusion compared with sustained coronary artery patency were right coronary infarct-related artery (65% versus 44%, respectively) and Thrombolysis in Myocardial Infarction (TIMI) flow 0 or 1 (21% versus 10%, respectively) before further intervention. Median (interquartile value) degree of stenosis in the infarct-related artery at 90 minutes was similar between groups: 99% for reoccluded (value, 90/100%) compared with 95% for patent (value, 80/99%). Patients with reocclusion had similar left ventricular ejection fractions compared with patients with sustained patency at follow-up. However, patients with reocclusion at follow-up had worse infarct-zone function at -2.7 (value, -3.2/-1.8) versus -2.4 (SD/chord) (value, -3.1/-1.3) (p = 0.016). The recovery of both global and infarct-zone function was impaired by reocclusion of the infarct-related artery compared with maintained patency; median delta ejection fraction was -2 compared with 1 (p = 0.006) and median delta infarct-zone wall motion was -0.10 compared with 0.34 SD/chord (p = 0.011), respectively. In addition, patients with reocclusion had more complicated hospital courses and higher in-hospital mortality rates (11.0% versus 4.5%, respectively; p = 0.01). We conclude that reocclusion of the infarct-related artery after successful reperfusion is associated with substantial morbidity and mortality rates. Reocclusion is also detrimental to the functional recovery of both global and infarct-zone regional left ventricular function. Thus, new strategies in the postinfarction period need to be developed to prevent reocclusion of the infarct-related artery.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2394002     DOI: 10.1161/01.cir.82.3.781

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  52 in total

Review 1.  Advances in the medical management of acute coronary syndromes.

Authors:  C P Cannon
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

2.  Improving reperfusion after myocardial infarction.

Authors:  I B Menown; A A Adgey
Journal:  BMJ       Date:  1999-12-11

3.  Novel and Innovative Dosing Regimens in Thrombolytic Therapy for Acute Myocardial Infarction.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

4.  Enhancing Thrombolysis with Adjunctive Therapy.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

5.  Achieving Optimal Reperfusion without Adjunctive Antithrombotic Therapy: Novel Thrombolytic Dosing Strategies.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

6.  Thrombolytic Therapy: The Treatment of Choice in Acute Myocardial Infarction.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

Review 7.  Platelet activation in acute myocardial infarction and the rationale for combination therapy.

Authors:  I Conde-Pozzi; N Kleiman
Journal:  Curr Cardiol Rep       Date:  2000-09       Impact factor: 2.931

Review 8.  Current clinical use of reteplase for thrombolysis. A pharmacokinetic-pharmacodynamic perspective.

Authors:  U Martin; B Kaufmann; G Neugebauer
Journal:  Clin Pharmacokinet       Date:  1999-04       Impact factor: 6.447

9.  Impact of early accelerated dose tissue plasminogen activator on in-hospital patency of the infarcted vessel in patients with acute right ventricular infarction.

Authors:  E Giannitsis; J Potratz; U Wiegand; U Stierle; H Djonlagic; A Sheikhzadeh
Journal:  Heart       Date:  1997-06       Impact factor: 5.994

Review 10.  A new look at coronary angiograms: plaque morphology as a help to diagnosis and to evaluate outcome.

Authors:  J Lespérance; P Théroux; G Hudon; D Waters
Journal:  Int J Card Imaging       Date:  1994-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.